TY - JOUR
T1 - Effects of high-dose and conventional-dose adjuvant chemotherapy on long-term cognitive sequelae in breast cancer patients: An electrophysiologic study
T2 - An electrophysiologic study
AU - Kreukels, B.P.C.
AU - Ridderinkhof, K.R.
AU - Boogerd, W.
AU - Hamburger, H.L.
AU - Muller, M.M.
AU - van Dam, F.S.A.M.
AU - Muller, Martin J.
PY - 2006/1/1
Y1 - 2006/1/1
N2 - Background: The mechanisms underlying cognitive deficits found in a number of patients with breast cancer treated with adjuvant chemotherapy are still unclear. In the current study, we used a combination of measures of brain electric activity and cognitive performance during information processing to elucidate the origin of these cognitive deficits. Patients and Methods: Twenty-nine patients at high risk with breast cancer treated with adjuvant conventional-dose cyclophosphamide/ epirubicin/5-fluorouracil or adjuvant high-dose cyclophosphamide/ thiotepa/carboplatin were compared with 23 patients with stage I breast cancer not treated with chemotherapy approximately 4 years after completion of treatment. We studied reaction times and the amplitudes and latencies of the P3, an electrophysiologic index of information processing, in a task with different conditions related to input, central, and output processing of information. Results: The amplitude of the P3 component was significantly reduced in patients with breast cancer treated with high-dose cyclophosphamide/ thiotepa/carboplatin compared with patients with breast cancer not treated with chemotherapy. We observed no significant differences in reaction times and P3 latency between the treatment groups. Conclusion: Our data show electrophysiologic alterations in patients with breast cancer treated with high-dose chemotherapy 4 years after completion of treatment. The observed P3 reduction might be a result of suboptimal phasic cortical arousal and problems with the allocation of processing resources in these patients.
AB - Background: The mechanisms underlying cognitive deficits found in a number of patients with breast cancer treated with adjuvant chemotherapy are still unclear. In the current study, we used a combination of measures of brain electric activity and cognitive performance during information processing to elucidate the origin of these cognitive deficits. Patients and Methods: Twenty-nine patients at high risk with breast cancer treated with adjuvant conventional-dose cyclophosphamide/ epirubicin/5-fluorouracil or adjuvant high-dose cyclophosphamide/ thiotepa/carboplatin were compared with 23 patients with stage I breast cancer not treated with chemotherapy approximately 4 years after completion of treatment. We studied reaction times and the amplitudes and latencies of the P3, an electrophysiologic index of information processing, in a task with different conditions related to input, central, and output processing of information. Results: The amplitude of the P3 component was significantly reduced in patients with breast cancer treated with high-dose cyclophosphamide/ thiotepa/carboplatin compared with patients with breast cancer not treated with chemotherapy. We observed no significant differences in reaction times and P3 latency between the treatment groups. Conclusion: Our data show electrophysiologic alterations in patients with breast cancer treated with high-dose chemotherapy 4 years after completion of treatment. The observed P3 reduction might be a result of suboptimal phasic cortical arousal and problems with the allocation of processing resources in these patients.
KW - Cognitive deficits
KW - Information processing
KW - Long-term side effects
KW - Neurotoxicity
KW - P3
UR - http://www.scopus.com/inward/record.url?scp=33744967562&partnerID=8YFLogxK
U2 - https://doi.org/10.3816/CBC.2006.n.015
DO - https://doi.org/10.3816/CBC.2006.n.015
M3 - Article
SN - 1526-8209
VL - 7
SP - 67
EP - 78
JO - Clinical Breast Cancer
JF - Clinical Breast Cancer
IS - 1
ER -